Patents by Inventor Jason G. Beaudet

Jason G. Beaudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TMEFF1 antibodies and antibody drug conjugates
    Patent number: 11981732
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: May 14, 2024
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • Anti-VTCN1 antibodies and antibody drug conjugates
    Patent number: 11932694
    Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 19, 2024
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
  • ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230331839
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 28, 2023
    Publication date: October 19, 2023
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • Anti-SEZ6L2 antibodies and antibody drug conjugates
    Patent number: 11634486
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 25, 2023
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20230069760
    Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 2, 2023
    Applicants: Bluefin BioMedicine, Inc., Bluefin BioMedicine, Inc.
    Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
  • ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20220298239
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 22, 2022
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20220267455
    Abstract: Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: December 22, 2021
    Publication date: August 25, 2022
    Inventors: Tinglei Gu, Scott Michael Lonning, Jason G. Beaudet, Sean A. Beausoleil, Nels Eric Pederson, Daniel Mulhern
  • Anti-TMEFF1 antibodies and antibody drug conjugates
    Patent number: 11312769
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 26, 2022
    Assignee: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
  • Anti-IL1RAP antibodies and antibody drug conjugates
    Patent number: 11248054
    Abstract: Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 15, 2022
    Assignee: BLUEFIN BIOMEDICINE, INC.
    Inventors: Tinglei Gu, Scott Michael Lonning, Jason G. Beaudet, Sean A. Beausoleil, Nels Eric Pederson, Daniel Mulhern
  • ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20210130454
    Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody dmg conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 6, 2021
    Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
  • ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200140561
    Abstract: Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 12, 2018
    Publication date: May 7, 2020
    Inventors: Tinglei Gu, Scott Michael Lonning, Jason G. Beaudet, Sean A. Beausoleil, Nels Eric Pederson, Daniel Mulhern
  • ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200109194
    Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 9, 2020
    Applicant: Bluefin BioMedicine, Inc.
    Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet